epocrates logo
epocrates logo
epocrates logo
  • 0

Diseases

Motion sickness

OVERVIEW

  • Highlights & Basics
  • Images

DIAGNOSIS

  • Diagnostic Approach
  • Risk Factors
  • History & Exam
  • Tests
  • Differential Diagnosis
  • Criteria
  • Screening

TREATMENT

  • Tx Approach
  • Tx Options
  • Emerging Tx
  • Prevention

FOLLOW-UP

  • Overview
  • Complications

REFERENCES

  • Citations
  • Guidelines
  • Credits

PATIENT RESOURCES

  • Patient Instructions

Highlights & Basics

AAFont SizeShareMore Information
Key Highlights
  • Motion sickness is a common condition provoked by physical motion or visual motion. 

  • Characterized by nausea/vomiting, possibly accompanied by other symptoms such as dizziness, vertigo, or headache. 

  • Controlled breathing might be helpful to counteract symptoms of motion sickness.

  • Drug therapy includes antimuscarinics and antihistamines; however both may have significant adverse effects (notably drowsiness) and impede habituation (desensitization). 

  • Habituation and cognitive behavioral therapy may be useful for people who must undergo repeated provocative motion (e.g., occupational exposures).

Quick Reference

  • History & Exam

    • Key Factors

      • Other Factors

        More information...
      • Diagnostics Tests

          More information...
        • Treatment Options

            More information...

          Definition

          Epidemiology

          Etiology

          Pathophysiology

          content by BMJ Group
          Last updated

          Citations

            Key Articles

            • Cha YH, Golding JF, Keshavarz B, et al. Motion sickness diagnostic criteria: consensus document of the Classification Committee of the Bárány Society. J Vestib Res. 2021;31(5):327-44.[Abstract][Full Text]

            • Centers for Disease Control and Prevention. CDC Yellow Book 2026: health information for international travel. Section 7: travel by air and sea - motion sickness. Apr 2025 [internet publication].[Full Text]

            Referenced Articles

            • 1. Cha YH, Golding JF, Keshavarz B, et al. Motion sickness diagnostic criteria: consensus document of the Classification Committee of the Bárány Society. J Vestib Res. 2021;31(5):327-44.[Abstract][Full Text]

            • 2. Reason JT, Graybiel A. Changes in subjective estimates of well-being during the onset and remission of motion sickness symptomatology in the slow rotation room. Aerosp Med. 1970 Feb;41(2):166-71.

            • 3. Hu S, Grant WF, Stern RM, et al. Motion sickness severity and physiological correlates during repeated exposures to a rotating optokinetic drum. Aviat Space Environ Med. 1991;62:308-314.[Abstract]

            • 4. Guerraz M, Yardley L, Bertholon P, et al. Visual vertigo: symptom assessment, spatial orientation and postural control. Brain. 2001;124:1646-56.[Abstract][Full Text]

            • 5. Stanney KM, Hale KS, Nahmens I, et al. What to expect from immersive virtual environment exposure: influences of gender, body mass index, and past experience. Hum Factors. 2003;45:504-520.[Abstract]

            • 6. Kennedy RS, Fowlkes JE. Simulator sickness is polygenic and polysymptomatic: implications for research. Int J Aviat Psychol. 1992;2:23-38.

            • 7. Kennedy R, Lane N, Lilienthal M, et al. Profile analysis of simulator sickness symptoms: application to virtual reality environments. Presence. 1992;1:295-301.

            • 8. Golding JF, Stott JR. Effect of sickness severity on habituation to repeated motion challenges in aircrew referred for airsickness treatment. Aviat Space Environ Med. 1995;66:625-630.[Abstract]

            • 9. Centers for Disease Control and Prevention. CDC Yellow Book 2026: health information for international travel. Section 7: travel by air and sea - motion sickness. Apr 2025 [internet publication].[Full Text]

            • 10. Bronstein AM, Golding JF, Gresty MA. Visual vertigo, motion sickness, and disorientation in vehicles. Semin Neurol. 2020 Feb;40(1):116-29.[Abstract]

            • 11. Keshavarz B, Golding JF. Motion sickness: current concepts and management. Curr Opin Neurol. 2022 Feb 1;35(1):107-12.[Abstract]

            • 12. Turner M, Griffin MJ. Motion sickness in public road transport: passenger behavior and susceptibility. Ergonomics. 1999;42:444-461.[Abstract]

            • 13. Flanagan MB, May JG, Dobie TG. Sex differences in tolerance to visually-induced motion sickness. Aviat Space Environ Med. 2005;76:642-46.[Abstract]

            • 14. Kennedy RS, Lanham DS, Massey CJ, et al. Gender differences in simulator sickness incidence: implications for military virtual reality systems. Safe J. 1995;25:69-76.

            • 15. Klosterhalfen S, Kellermann S, Pan F, et al. Effects of ethnicity and gender on motion sickness susceptibility. Aviat Space Environ Med. 2005;76:1051-1057.[Abstract]

            • 16. Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med. 1988;59:399-406.[Abstract]

            • 17. Stern RM, Hu S, LeBlanc R, et al. Chinese hyper-susceptibility to vection-induced motion sickness. Aviat Space Environ Med. 1993;64: 827-830.[Abstract]

            • 18. Zhang LL, Wang JQ, Qi RR, et al. Motion sickness: current knowledge and recent advance. CNS Neurosci Ther. 2016 Jan;22(1):15-24.[Abstract]

            • 19. Golding JF, Mueller AG, Gresty MA. A motion sickness maximum around the 0.2 Hz frequency range of horizontal translational oscillation. Aviat Space Environ Med. 2001;72:188-192.[Abstract]

            • 20. Lawther A, Griffin MJ. Prediction of the incidence of motion sickness from the magnitude, frequency, and duration of vertical oscillation. J Acoust Soc Am. 1987;82:957-966.[Abstract]

            • 21. O'Hanlon JF, McCauley ME. Motion sickness incidence as a function of the frequency and acceleration of vertical sinusoidal motion. Aerosp Med. 1974;45:366-369.[Abstract]

            • 22. Bijveld MM, Bronstein AM, Golding JF, et al. Nauseogenicity of off-vertical axis rotation vs. equivalent visual motion. Aviat Space Environ Med. 2008;79:661-665.[Abstract]

            • 23. Drummond PD. Triggers of motion sickness in migraine sufferers. Headache. 2005;45:653-656.[Abstract]

            • 24. Huang TC, Wang SJ, Kheradmand A. Vestibular migraine: an update on current understanding and future directions. Cephalalgia. 2020 Jan;40(1):107-21.[Abstract][Full Text]

            • 25. Arshad Q, Moreno-Ajona D, Goadsby PJ, et al. What visuospatial perception has taught us about the pathophysiology of vestibular migraine. Curr Opin Neurol. 2024 Feb 1;37(1):32-9.[Abstract]

            • 26. Stern RM, Koch KL, Stewart WR, et al. Spectral analysis of tachygastria recorded during motion sickness. Gastroenterol. 1987;92:92-97.[Abstract]

            • 27. Neimer J, Eskiizmirliler S, Ventre-Dominey J, et al. Trains with a view to sickness. Curr Biol. 2001;11:R549-R550.[Abstract]

            • 28. Williamson MJ, Thomas MJ, Stern RM. The contribution of expectations to motion sickness symptoms and gastric activity. Psychosom Res. 2004;56:721-6.[Abstract]

            • 29. Houchens PW, Jones MB. Behavioral contagion in an experimental motion environment. Aviat Space Environ Med. 2003;74:649-653.[Abstract]

            • 30. Zajonc TP, Roland PS. Vertigo and motion sickness. Part II: Pharmacologic treatment. Ear Nose Throat J. 2006;85:25-35.[Abstract]

            • 31. Zajonc TP, Roland PS. Vertigo and motion sickness. Part I: vestibular anatomy and physiology. Ear Nose Throat J. 2005;84:581-584.[Abstract]

            • 32. Ventre-Dominey J, Luyat M, Denise P, et al. Motion sickness induced by otolith stimulation is correlated with otolith-induced eye movements. Neuroscience. 2008;155:771-779.[Abstract]

            • 33. Dai M, Kunin M, Raphan T, et al. The relation of motion sickness to the spatial-temporal properties of velocity storage. Exp Brain Res. 2003;151:173-189.[Abstract]

            • 34. Cohen B, Dai M, Yakushin SB, et al. Baclofen, motion sickness susceptibility and the neural basis for velocity storage. Prog Brain Res. 2008;171:543-553.[Abstract]

            • 35. Dai M, Sofroniou S, Kunin M, et al. Motion sickness induced by off-vertical axis rotation (OVAR). Exp Brain Res. 2010 Jul;204(2):207-22.[Abstract]

            • 36. Stern RM, Leibowitz HW, Unblad I, et al. Tachygastria and motion sickness. Aviat Space Environ Med. 1985;56:1074-1077.[Abstract]

            • 37. Drummond PD. Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. Neurology. 2005;65:620-622.[Abstract]

            • 38. von Reinhart J. Histamin-intoleranz: histamin und seekrankheit. Stuttgart: Thieme; 2004.

            • 39. Lichtenberg BK, Young LR, Arrott AP. Human ocular counterrolling induced by varying linear accelerations. Exp Brain Res. 1982;48:127-136.[Abstract]

            • 40. Merfeld DM, Park S, Gianna-Poulin C, et al. Vestibular perception and action employ qualitatively different mechanisms. II. VOR and perceptual responses during combined Tilt&Translation. J Neurophysiol. 2005;94:199-205.[Abstract][Full Text]

            • 41. Merfeld DM, Park S, Gianna-Poulin C, et al. Vestibular perception and action employ qualitatively different mechanisms. I. Frequency response of VOR and perceptual responses during Translation and Tilt. J Neurophysiol. 2005;94:186-198.[Abstract][Full Text]

            • 42. Wood SJ. Human otolith-ocular reflexes during off-vertical axis rotation: effect of frequency on tilt-translation ambiguity and motion sickness. Neurosci Lett. 2002;323:41-44.[Abstract]

            • 43. Kheradmand A, Winnick A. Perception of upright: multisensory convergence and the role of temporo-parietal cortex. Front Neurol. 2017;8:552.[Abstract][Full Text]

            • 44. Money KE, Cheung BS. Another function of the inner ear: facilitation of the emetic response to poisons. Aviat Space Environ Med. 1983;54:208-211.[Abstract]

            • 45. Treisman M. Motion sickness: an evolutionary hypothesis. Science. 1977;197:493-495.[Abstract]

            • 46. Yates BJ, Miller AD, Lucot JB. Physiological basis and pharmacology of motion sickness: an update. Brain Res Bull. 1998;47:395-406.[Abstract]

            • 47. Reavley CM, Golding JF, Cherkas LF, et al. Genetic influences on motion sickness susceptibility in adult women: a classical twin study. Aviat Space Environ Med. 2006 Nov;77(11):1148-52.[Abstract][Full Text]

            • 48. Drummond PD, Granston A. Facial pain increases nausea and headache during motion sickness in migraineurs. Brain. 2004;127:526-534.[Abstract]

            • 49. Murdin L, Chamberlain F, Cheema S, et al. Motion sickness in migraine and vestibular disorders. J Neurol Neurosurg Psychiatry. 2015 May;86(5):585-7.[Full Text]

            • 50. Pavlou M, Lingeswaran A, Davies RA, et al. Simulator based rehabilitation in refractory dizziness. J Neurol. 2004;251:983-95.[Abstract]

            • 51. Takahashi M, Okada Y, Saito A, et al. Locomotion and motion sickness under horizontal and vertical reversal of vision. Acta Otolaryngol Suppl. 1991;481:319-21.

            • 52. Lee SH, Kim M, Kim H, et al. Visual fatigue induced by watching virtual reality device and the effect of anisometropia. Ergonomics. 2021 Dec;64(12):1522-31.[Abstract]

            • 53. Golding JF, Prosyanikova O, Flynn M, et al. The effects of smoking nicotine tobacco versus smoking deprivation on motion sickness. Aviat Space Environ Med. 2008;79:262.

            • 54. Redfern MS, Furman JM, Jacob RG. Visually induced postural sway in anxiety disorders. J Anxiety Disord. 2007;21:704-716.[Abstract][Full Text]

            • 55. Redfern MS, Yardley L, Bronstein AM. Visual influences on balance. J Anxiety Disord. 2001;15:81-94.[Abstract]

            • 56. Romas RT, Jacob RG, Lilienfeld SO. Space and motion discomfort in Brazilian versus American patients with anxiety disorders. J Anxiety Disord. 1997;11:131-139.[Abstract]

            • 57. Golding JF, Kadzere P, Gresty MA. Motion sickness susceptibility fluctuates through the menstrual cycle. Aviat Space Environ Med. 2005:76; 970-973.[Abstract]

            • 58. Saman Y, Sharif M, Lee A, et al. Sex-disease dimorphism underpins enhanced motion sickness susceptibility in primary adrenal insufficiency: a cross-sectional observational study. Exp Brain Res. 2023 Apr;241(4):1199-206.[Abstract]

            • 59. Stern RM, Hu S, Anderson RB, et al. The effects of fixation and restricted visual field on vection-induced motion sickness. Aviat Space Environ Med. 1990;61:712-715.[Abstract]

            • 60. Streitberger K, Ezzo J, Schneider A. Acupuncture for nausea and vomiting: an update of clinical and experimental studies. Auton Neurosci. 2006;129:107-17.[Abstract]

            • 61. Hu S, Stern RM, Koch KL. Electrical acustimulation relieves vection-induced motion sickness. Gastroenterology. 1992;102:1854-8.[Abstract]

            • 62. Denise P, Vouriot A, Normand H, et al. Effect of temporal relationship between respiration and body motion on motion sickness. Auton Neurosci. 2009;151:142-6.[Abstract]

            • 63. Rahimzadeh G, Tay A, Travica N, et al. Nutritional and behavioral countermeasures as medication approaches to relieve motion sickness: a comprehensive review. Nutrients. 2023 Mar 7;15(6):1320.[Abstract][Full Text]

            • 64. Leung AK, Hon KL. Motion sickness: an overview. Drugs Context. 2019;8:2019-9-4.[Abstract][Full Text]

            • 65. Golding JF. Predicting individual differences in motion sickness susceptibility by questionnaire. Pers Individ Dif. 2006;41:237-248.

            • 66. Jokerst MD, Gatto M, Fazio R, et al. Slow deep breathing prevents the development of tachygastria and symptoms of motion sickness. Aviat Space Environ Med. 1999;70:1189-1192.[Abstract]

            • 67. Yen Pik Sang F, Billar JP, Gresty MA, et al. Effect of a novel motion desensitization training regime and controlled breathing on habituation to motion sickness. Percept Mot Skills. 2005;101:244-256.[Abstract]

            • 68. Yen Pik Sang FD, Billar JP, Golding JF, et al. Behavioral methods of alleviating motion sickness: effectiveness of controlled breathing and a music audiotape. J Travel Med. 2003;10:108-11.[Abstract][Full Text]

            • 69. Yen Pik Sang FD, Golding JF, Gresty MA. Suppression of sickness by controlled breathing during mildly nauseogenic motion. Aviat Space Environ Med. 2003;74:998-1002.[Abstract]

            • 70. Fiori F, David N, Aglioti SM. Processing of proprioceptive and vestibular body signals and self-transcendence in Ashtanga yoga practitioners. Front Hum Neurosci. 2014 Sep 18:8:734.[Abstract][Full Text]

            • 71. Nigmatullina Y, Hellyer PJ, Nachev P, et al. The neuroanatomical correlates of training-related perceptuo-reflex uncoupling in dancers. Cereb Cortex. 2015 Feb;25(2):554-62.[Abstract][Full Text]

            • 72. Stewart JJ, Wood MJ, Parish RC, et al. Prokinetic effects of erythromycin after antimotion sickness drugs. J Clin Pharmacol. 2000;40:347-353.[Abstract]

            • 73. Wood CD, Graybiel A. Evaluation of 16 antimotion sickness drugs under controlled laboratory conditions. Aerospace Med. 1968;39:1341-1344.

            • 74. Karrim N, Byrne R, Magula N, et al. Antihistamines for motion sickness. Cochrane Database Syst Rev. 2022 Oct 17;10(10):CD012715.[Abstract][Full Text]

            • 75. Spinks AB, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev. 2011;(6):CD002851.[Abstract][Full Text]

            • 76. Burton MJ, Roland PS, Rosenfeld RM. Extracts from The Cochrane Library: Scopolamine (hyoscine) for preventing and treating motion sickness. Otolaryngol Head Neck Surg. 2010;142:468-471.[Abstract]

            • 77. Bar R, Gil A, Tal D. Safety of double-dose transdermal scopolamine. Pharmacotherapy. 2009;29:1082-1088.[Abstract]

            • 78. Howland J, Rohsenow DJ, Minsky S, et al. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time. Int J Occup Environ Health. 2008;14:250-256.[Abstract]

            • 79. US Food and Drug Administration. ​FDA adds warning about serious risk of heat-related complications with antinausea patch Transderm Scōp (scopolamine transdermal system). Jun 2025 [internet publication].​[Full Text]

            • 80. Joo JH. Anisocoria after scopolamine transdermal patch contamination: a case report. Medicine (Baltimore). 2021 Nov 19;100(46):e27887.[Abstract][Full Text]

            • 81. Shah J, Jiang A, Fekete Z. Anisocoria secondary to inadvertent contact with scopolamine patch. BMJ Case Rep. 2017 Sep 19;2017:bcr2017221677.[Abstract][Full Text]

            • 82. Cowings PS, Toscano WB. Autogenic-feedback training exercise is superior to promethazine for control of motion sickness symptoms. J Clin Pharmacol. 2000;40:1154-65.[Abstract]

            • 83. Golding JF, Stott JR. Objective and subjective time courses of recovery from motion sickness assessed by repeated motion challenges. J Vestib Res. 1997;7:421-428.[Abstract]

            • 84. Stern RM, Hu SQ, Vasey MW, et al. Adaptation to vection-induced symptoms of motion sickness. Aviat Space Environ Med. 1989 Jun;60(6):566-72.[Abstract][Full Text]

            • 85. Ressiot E, Dolz M, Bonne L, et al. Prospective study on the efficacy of optokinetic training in the treatment of seasickness. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130:263-268.[Abstract]

            • 86. Stroud KJ, Harm DL, Klaus DM. Preflight virtual reality training as a countermeasure for space motion sickness and disorientation. Aviat Space Environ Med. 2005;76:352-356.[Abstract]

            • 87. Dobie TG, May JG. Cognitive-behavioural management of motion sickness. Aviat Space Environ Med. 1994;65:C1-C2.[Abstract]

            • 88. Toscano WB, Cowings PS. Reducing motion sickness: a comparison of autogenic-feedback training and an alternative cognitive task. Aviat Space Environ Med. 1982;53:449-453.[Abstract]

            • 89. Polymeropoulos VM, Kiely L, Bushman ML, et al. Motion Syros: tradipitant effective in the treatment of motion sickness; a multicenter, randomized, double-blind, placebo-controlled study. Front Neurol. 2025;16:1550670.[Abstract][Full Text]

            • 90. ​ClinicalTrials.gov. Motion serifos: a study to investigate the efficacy of tradipitant in participants affected by motion sickness.ClinicalTrials.gov Identifier: NCT05903924. Apr 2025 [internet publication].[Full Text]

            • 91. Javid FA, Naylor RJ. The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. Pharmacol Biochem Behav. 2002;73:979-989.[Abstract]

            • 92. Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med Sci Monit. 2006;12:PI1-PI7.[Abstract]

            • 93. Furman JM, Marcus DA, Balaban CD. Rizatriptan reduces vestibular-induced motion sickness in migraineurs. J Headache Pain. 2011 Feb;12(1):81-8.[Abstract][Full Text]

            • 94. Klocker N, Hanschke W, Toussaint S, et al. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur J Pharm Sci. 2001;13:227-232.[Abstract]

            • 95. Ahmed S, Sileno AP, de Meireles JC, et al. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm Res. 2000;17:974-977.[Abstract]

            • 96. Simmons RG, Phillips JB, Lojewski RA, et al. The efficacy of low-dose intranasal scopolamine for motion sickness. Aviat Space Environ Med. 2010;81:405-412.[Abstract]

            • 97. Stankovic AS, Alvarenga DL, Coleman Daniels VR, et al. Intranasal scopolamine for motion sickness. Aerosp Med Hum Perform. 2019 Nov 1;90(11):917-24.[Abstract][Full Text]

            • 98. Yang M, Li Z, Pan F, et al. Alpha tACS on parieto-occipital cortex mitigates motion sickness based on multiple physiological observation. IEEE Trans Neural Syst Rehabil Eng. 2024;32:2398-407.[Abstract][Full Text]

            • 99. Li G, Zanto T. Reduced VR motion sickness by applying random-phase transcranial alternating current stimulation to the left parietal cortex. Brain Stimul. 2024 May-Jun;17(3):550-2.[Full Text]

            • 100. Takeuchi N, Mori T, Suzukamo Y, et al. Modulation of excitability in the temporoparietal junction relieves virtual reality sickness. Cyberpsychol Behav Soc Netw. 2018 Jun;21(6):381-7.[Abstract]

            • 101. Arshad Q, Cerchiai N, Goga U, et al. Electrocortical therapy for motion sickness. Neurology. 2015 Oct 6;85(14):1257-9.[Full Text]

            • 102. Grunfeld E, Price C, Goadsby P, et al. Migraine, motion sickness and menstruation in mariners. Lancet. 1998;351:1106.[Abstract]

          Have feedback?
          Tell us about your experience
          epocrates logo

          Sign in to access our clinical decision support tools

          Sign inCreate Account
          Download Epocrates from the App StoreDownload Epocrates from the Play Store
          About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
          © 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information